Fly News Breaks for March 20, 2017
Mar 20, 2017 | 07:07 EDT
SunTrust analyst Sandy Draper identifies PRA Health as his favorite late-stage contract research organization, or CRO. The analyst expects the company's partnerships to drive double digit percentage revenue growth through at least 2018. Draper says that the company has high quality bookings, and he raised his price target on the shares to $72 from $70. He keeps a Buy rating on the stock.
News For PRAH From the Last 2 Days
Aug 16, 2017 | 16:34 EDT
Raymond James analyst Michael Baker initiated PRA Health with an Outperform and an $89 price target telling investors it is one of the fasts growing contract research organizations, or CRO, that offers clients an innovative approach to to clinical development that has gained significant traction among large pharma client segment. Further, he expects two recent strategic partnerships, strong bookings growth, and peers tied up in large-scale M&A should translate to higher 2018 revenue and EPS than consensus expects.